Heteroduplex Oligonucleotide Inhibition of IHH for Fibrosis Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies for fibrosis, particularly in conditions like nonalcoholic steatohepatitis (NASH), lack effective mechanisms and FDA-approved treatments, with existing antifibrotic agents like Pirfenidone and Nintedanib having limited efficacy and novel action mechanisms being desired.
Innovation Solution
Development of a nucleic acid complex comprising a heteroduplex oligonucleotide (HDO) that specifically targets and inhibits Indian hedgehog (IHH) gene expression, utilizing complementary oligonucleotides to suppress IHH gene transcription products, thereby regulating fibrosis progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antifibrotic agents (Pirfenidone, Nintedanib) are used for treating fibrosis, then some therapeutic effect is achieved, but their efficacy is limited and novel action mechanisms are needed
Solution Approach 1:
The patent uses heteroduplex oligonucleotides as intermediary molecules that specifically bind to IHH mRNA transcripts, preventing their translation into protein. This mediator approach provides a novel mechanism distinct from existing antifibrotics, targeting the IHH signaling pathway directly through nucleic acid hybridization rather than small molecule receptor binding
Solution Approach 2:
The invention replaces the small molecule drug mechanism with a nucleic acid-based mechanism. Instead of using small molecules that bind to proteins, the patent employs oligonucleotide sequences that hybridize to complementary mRNA sequences, utilizing nucleic acid hybridization physics rather than traditional pharmacological binding
2Reliability
If IHH gene expression is inhibited using nucleic acid complex, then fibrosis progression is regulated, but the complexity of the nucleic acid complex increases
Solution Approach 1:
The complex nucleic acid structure is segmented into functional domains: a 5' wing region for stability and cellular uptake, a central gap region for RNase H recruitment and mRNA cleavage, and a 3' wing region for additional stability. This segmentation allows each region to be optimized independently for its specific function while maintaining overall efficacy
Solution Approach 2:
The patent optimizes specific parameters of the oligonucleotide structure including length (12-30 nucleotides in gap region), GC content (40-60%), and modification patterns (phosphorothioate at termini, 2'-O-methyl modifications) to balance stability, specificity, and biological activity, reducing the need for overly complex structures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The HDO effectively inhibits IHH gene expression, reducing fibrosis markers and improving liver health in NASH models, demonstrating potential therapeutic benefits for fibrotic conditions in various tissues.
Implementation Method 1
a nucleic acid complex comprising a heteroduplex oligonucleotide (HDO) for regulating expression of the Indian hedgehog gene
Implementation Method 2
an oligonucleotide having a nucleic acid base sequence complementary to an IHH gene transcription product
Data Source
AI summary
This invention provides a nucleic acid complex and a method for decreasing the expression levels of mRNA and a protein of the IHH gene in animals. The nucleic acid complex for decreasing the expression levels of mRNA and a protein of the IHH gene serves as an IHH-specific inhibitor and it is thus useful for elucidation of IHH gene functions. In addition, an IHH-specific inhibitor is useful for treatment, prevention, amelioration, or delaying of the progression of fibrosis and other fibrotic diseases. Since the nucleic acid complex according to the present invention specifically inhibits IHH gene expression, it is useful for a patient who is in need of treatment, prevention, amelioration, or delaying of the progression of fibrosis and other fibrotic diseases.